Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case -88% Improvement Relative Risk Case (b) 8% c19hcq.org Shahrin et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 336 patients in Bangladesh (March - July 2020) More cases with HCQ (not stat. sig., p=0.088) Shahrin et al., Life, doi:10.3390/life12122047 Favors HCQ Favors control
Hospital-Based Quasi-Experimental Study on Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Providers with Its Potential Side-Effects
Shahrin et al., Life, doi:10.3390/life12122047
Shahrin et al., Hospital-Based Quasi-Experimental Study on Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in.., Life, doi:10.3390/life12122047
Dec 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 230 low risk healthcare workers taking HCQ prophylaxis, and 106 that declined, showing higher cases without statistical significance. No case severity information is provided. The point estimate favored HCQ when excluding the first 14 days and including participants that worked for at least 16 days. Authors note a significant dose response relationship.
risk of case, 87.8% higher, RR 1.88, p = 0.09, treatment 43 of 230 (18.7%), control 11 of 106 (10.4%), adjusted per study, odds ratio converted to relative risk, multivariable.
risk of case, 8.0% lower, OR 0.92, p = 0.89, adjusted per study, excluding the first 14 days and including participants that worked for at least 16 days, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shahrin et al., 7 Dec 2022, retrospective, Bangladesh, peer-reviewed, median age 34.0, 11 authors, study period 31 March, 2020 - 12 July, 2020.
Contact: lubabashahrin@icddrb.org (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: life Article Hospital-Based Quasi-Experimental Study on Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Providers with Its Potential Side-Effects Lubaba Shahrin 1,2, * , Mustafa Mahfuz 2 , Md. Waliur Rahman 2 , Md. Rezaul Hossain 3 , Afsana Mim Khandaker 4 , Md. Ashraful Alam 2 , Din M. M. F. Osmany 5 , Md. Munirul Islam 2 , Mohammod Jobayer Chisti 1,2 , Chaudhury Meshkat Ahmed 5 and Tahmeed Ahmed 2 1 2 3 4 5 * Citation: Shahrin, L.; Mahfuz, M.; Rahman, M.W.; Hossain, M.R.; Khandaker, A.M.; Alam, M.A.; Osmany, D.M.M.F.; Islam, M.M.; Chisti, M.J.; Ahmed, C.M.; et al. Hospital-Based Quasi-Experimental Study on Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Providers with Its Potential Side-Effects. Life 2022, 12, 2047. https://doi.org/ 10.3390/life12122047 Academic Editor: Simona Zaami Received: 22 October 2022 Accepted: 30 November 2022 Published: 7 December 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in Dhaka Hospital, International Centre for Diarrheal Disease Research, Bangladesh (icddr, b), Dhaka 1212, Bangladesh Nutrition and Clinical Services Division, International Centre for Diarrheal Disease Research, Bangladesh (icddr, b), Dhaka 1212, Bangladesh Department of Epidemiology, University of Washington, Seattle, WA 98195, USA Department of Nutrition, University of Nevada, Reno, NV 89557, USA Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka 1000, Bangladesh Correspondence: lubabashahrin@icddrb.org; Tel.: +880-2-8860523-32 (ext. 2303); Fax: +880-2-882-3116 or +880-2-988-5657 Abstract: Considering that it has been more than 24 months since SARS-CoV-2 emerged, it is crucial to identify measures that prevent and control pathogen transmission in workplace settings. Our aim was to report results of a hospital-based program that delivered hydroxychloroquine (HCQ) tablets as COVID-19 prophylaxis to the frontline healthcare workers (HCW)s who cared for COVID-19 patients and to evaluate the efficacy of HCQ. Setting and participants: Quasi-experimental, controlled, single-center study. The included participants were doctors, nurses, health workers, cleaning staff, and non-healthcare supportive staff. The main outcome was contracting COVID-19 anytime during the period of taking the prophylaxis, confirmed by RT-PCR. A total of 336 participants, without any clinical evidence of COVID-19 and without any known contact with family members, were included in the trial; 230 were assigned to HCQ and 106 declined to take any drug. Results: Among the participants, 43 (18.7%) in the HCQ group and 11 (10.4%) participants in the control group developed COVID-19. For the evaluation of side effects, we evaluated 12-lead ECGs of both groups at the baseline and after 4 weeks to monitor QTc interval. A total of 91% (198 of 217) participants in the prophylaxis group and 92% (11 of 12) in the control group had a QTc < 45o msec, which is within normal limits. Conclusions: Although the number of symptomatic infections in health personnel was lower in the control group, the difference was not statistically significant. However, in the absence of any effective pre-exposure prophylaxis medicine for COVID-19, practicing proper infection prevention and control (IPC) and vaccination is the only way forward. Keywords: hydroxychloroquine; COVID-19; preexposure prophylaxis; corrected QT interval; healthcare workers published maps and institutional..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit